ARVO 2025: PAVIA 12-month results in nonproliferative diabetic retinopathy

At ARVO 2025, in Salt Lake City, Utah, David Almeida, MD, MBA, PhD, talked about 12-month results from the PAVIA phase 2 trial of EYP-1901 in nonproliferative diabetic retinopathy.

Video Transcript:

Editor's note: The below transcript has been lightly edited for clarity.

David Almeida, MD, MBA, PhD:

My name is David Almeida. I'm a vitreoretinal surgeon and clinician scientist at Erie Retin Research. It's wonderful to be here at ARVO at South Lake City for 2025. I'll be presenting the EyePoint abstract poster on the clinical trial PAVIA.

This is a clinical trial looking at patients with non-proliferative diabetic retinopathy and looking at diabetic retinopathy regression scores. What we saw is that, at 6 months, we saw improvements in the treatment group and the EyePoint relevant group. Those treatment effects are still present 9 months, and we see a decrease in 12 months, likely showing the duration of effect. There was no new safety signals. This was tolerated well by the population, and we hope that we could see further programs here, as this is something that we hope diabetic patients can have access to as a way to reverse their disease states and have better visual outcomes in the long term.

In PAVIA, Eyepoint designed essentially 3 arms, so that they were going to get either a 2 milligram dose of vorolanib, but 3 milligram dose, or against sham. So there's really no standard of care yet established for nonprolife diabetic retinopathy. The treatment were every 6 months, so patients were essentially in a cap, where they had to receive every 6 months, and then this allowed for the regression to be seen at both month 6, 9, and then with no additional changes at month 12. Topline and really trying to extrapolate to the clinic, what we hope this brings is therapeutics for non-proliferative diabetic retinopathy. We know that the disease advances, and there's significant vision loss and inability to regress it once we have 2 proliferative stages. So anything that we could regress 2 or 3 steps in the non-proliferative diabetic retinopathy population, this will be a benefit. Also important is going to be the treatment burden. This is something that was treated every 6 months, so we're not asking patients come back super frequently for treatment. This will be important in diabetic populations. This is a younger working population.